INCY Stock Recent News

INCY LATEST HEADLINES

INCY Stock News Image - globenewswire.com

MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V.

globenewswire.com 2025 Mar 26
INCY Stock News Image - fool.com

A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (INCY 2.23%) stock over the past few days. The gloom this produced was pushing the biotech's share price down by nearly 11% week to date as of Friday before market open.

fool.com 2025 Mar 21
INCY Stock News Image - zacks.com

Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.

zacks.com 2025 Mar 18
INCY Stock News Image - seekingalpha.com

Statistical significance achieved with both doses of povorcitinib in both phase 3 STOP-HS studies treating patients with Hidradenitis suppurativa. The global Hidradenitis Suppurativa market size is expected to be worth $1.57 billion by 2031; Incyte can do well in biologic experienced HS patients. Regulatory discussions possible of expanded approval of OPZELURA for Prurigo Nodularis patients; However, regulatory discussion will be needed to determine if one phase 3 study will be enough for filing.

seekingalpha.com 2025 Mar 18
INCY Stock News Image - investopedia.com

Shares of Incyte (INCY) sank nearly 10% Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.

investopedia.com 2025 Mar 17
INCY Stock News Image - barrons.com

The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn't think it was enough.

barrons.com 2025 Mar 17
INCY Stock News Image - schaeffersresearch.com

Incyte Corp  (NASDAQ:INCY) stock is down 11.4% to trade at $60.16 at last glance, after the pharmaceutical company's phase three trial data for its skin disease treatment showed it was only effective for half of participants.

schaeffersresearch.com 2025 Mar 17
INCY Stock News Image - benzinga.com

On Monday, Incyte Corporation INCY released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS).

benzinga.com 2025 Mar 17
INCY Stock News Image - benzinga.com

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.

benzinga.com 2025 Mar 17
INCY Stock News Image - reuters.com

Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.

reuters.com 2025 Mar 17
10 of 50